Thalamic Recording in StereoEEG: Standard Practice or Research Requiring IRB Approval?
Overview
This editorial discusses the debate among international epilepsy experts regarding whether thalamic implantation during stereoEEG (SEEG) should be considered standard clinical care or remain a research activity requiring institutional review board (IRB) approval. While proponents highlight safety and clinical benefits, opponents emphasize the lack of randomized controlled trial evidence and advocate for its classification as research.
Background
StereoEEG is an invasive diagnostic procedure used to localize seizure onset zones in patients considered for epilepsy surgery by implanting intracerebral electrodes. Traditionally, SEEG targets brain regions generating focal seizures, excluding the thalamus. Recently, thalamic implantation has gained attention for its potential to map seizure networks and guide treatment, but its clinical utility and safety profile remain debated. Ethical considerations, patient safety, and the strength of evidence supporting thalamic SEEG are central to this discussion.
Data Highlights
Key points include: proponents cite safety data from large series and regulatory compliance supporting thalamic SEEG as standard care; opponents note increased hemorrhage risk with additional electrodes and lack of evidence from blinded, controlled trials; variability in targeting and protocols across centers complicates interpretation; and collaborative data-sharing platforms may facilitate future research.
Key Findings
There is disagreement on whether thalamic SEEG provides direct patient benefit sufficient to be standard care or should be limited to IRB-approved research.
Proponents argue thalamic recordings aid in testing seizure network hypotheses and have historical precedent and regulatory compliance supporting their use.
Opponents emphasize the absence of randomized controlled trials demonstrating improved outcomes and caution against increased patient risk from additional electrode implantation.
Ethical concerns focus on balancing patient safety with the potential benefits of thalamic recordings and the risks of restricting access to potentially useful clinical information.
Collaborative platforms and advanced data analytics may help overcome variability and facilitate evidence generation.
The debate reflects broader challenges in adopting new medical practices without class I evidence, highlighting the need for well-designed clinical trials.
Clinical Implications
Clinicians and centers must carefully weigh the potential benefits of thalamic SEEG against the risks and current evidence limitations. Until robust clinical trial data are available, decisions should consider patient safety, institutional expertise, and ethical standards. IRB-approved protocols may provide a structured framework for safely advancing thalamic SEEG research while protecting patients.
Conclusion
The question of whether thalamic SEEG is standard care or research remains unresolved due to differing expert opinions and limited high-quality evidence. Ongoing dialogue, collaborative research, and future clinical trials are essential to clarify its role in epilepsy management.
References
Editorial, Brain, 2024 -- Is Thalamic Recording in StereoEEG a Standard Practice or a Research Activity Requiring Institutional Review Board Approval?
